Orchid Pharma Q2 EBIDTA rises 104%, revenue up 36% on increasing sales
NEW DELHI: Orchid Pharma today announced their Q2’22 results. Fuelled by increasing sales and a laser sharp focus on costs, Orchid Pharma reported a 36% surge in total revenue from operations while the EBIDTA has jumped by 104% over the quarter ending September 2021. Dhanuka Group, through its pharmaceutical arm, Dhanuka Laboratories Ltd, had taken […]